Global Cancer Immunotherapies Market to 2024 - Increased Uptake of Immune Checkpoint Inhibitors Driving Growth, Supported by a Large, Robust Pipeline

  • ID: 4606290
  • Report
  • Region: Global
  • 215 pages
  • GBI Research
1 of 4

FEATURED COMPANIES

  • AbbVie
  • Amgen
  • AstraZeneca
  • Bristol-Myers Squibb
  • Celgene
  • Gilead Sciences
  • MORE
Global Cancer Immunotherapies Market to 2024 - Increased Uptake of Immune Checkpoint Inhibitors Driving Growth, Supported by a Large, Robust Pipeline

Summary

Cancer immunotherapy, which can predominantly be classed as a form of targeted therapy, drives an immune response against cancer cells. This may include stimulating a patient’s immune system in a general way or aiding the identification of specific antigens associated with the cancer.

The interest in cancer immunotherapy development has been driven by the growing understanding of the immune system as a hallmark of cancer pathophysiology, particularly immune evasion of developing cancer cells. Overall, 3,863 products are being actively developed in the cancer immunotherapy pipeline, approximately half of the overall oncology pipeline.

The report focuses on the key indications of breast cancer, leukemia, lymphoma, melanoma and non-small cell lung cancer, these indications are the largest in terms of size, with 448, 526, 456, 415 and 374 in active development, respectively. The pipeline is dominated mAbs, cell therapies, small molecules and cancer vaccines.

Scope
  • Global revenue from the cancer immunotherapies market is forecast to increase from $33.7 billion in 2017 to $103.4 billion in 2024, at a compound annual growth rate of 17.4%. What is driving this growth?
  • The leading companies in terms of market share are Celgene, Merck & Co., Bristol-Myers Squibb and Roche. Which of these are forecast to experience the largest growth?
  • There are some key new approvals and late-stage products set to enter the market during the forecast period. Which impact will these drugs have on the market?
  • The market has been dominated by immune checkpoint inhibitors and drugs that target tumor associated antigens. To what extent will these classes of drugs and others dominate the market over the forecast period?
  • There are 3,863 cancer immunotherapy products in the pipeline. What molecular targets are most abundant in the pipeline and what role will pipeline product approvals play in market growth?
  • Cancer immunotherapy clinical trials have an overall attrition rate of around 96%, what can companies do to maximize their chance of success?
Reasons to buy
  • Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action.
  • Analyze the cancer immunotherapy pipeline through a comprehensive review of the pipeline segmented by stage of development, molecule type and molecular target. This review also provides a detailed look at current cancer immunotherapies to provide an insight into the risk associated of attempting to bring pipeline products to market.
  • Predict growth in market size, with in-depth market forecasting from 2017 to 2024. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and certain patent expirations will influence market value.
  • Identify commercial opportunities in the cancer immunotherapies deals landscape by analyzing trends in licensing and co-development deals
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie
  • Amgen
  • AstraZeneca
  • Bristol-Myers Squibb
  • Celgene
  • Gilead Sciences
  • MORE

1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Therapy Area Introduction
2.2 Overview of Key Indications and Symptoms
2.2.1 Breast Cancer
2.2.2 Leukemia
2.2.3 Lymphoma
2.2.4 Melanoma
2.2.5 Non-Small Cell Lung Cancer
2.3 Diagnosis
2.3.1 Breast Cancer
2.3.2 Leukemia
2.3.3 Lymphoma
2.3.4 Melanoma
2.3.5 Non-Small Cell Lung Cancer
2.4 Etiology and Pathophysiology
2.4.1 Breast Cancer
2.4.2 Leukemia
2.4.3 Lymphoma
2.4.4 Melanoma
2.4.5 Non-Small Cell Lung Cancer
2.5 Epidemiology
2.5.1 Breast Cancer
2.5.2 Leukemia
2.5.3 Lymphoma
2.5.4 Melanoma
2.5.5 Non-Small Cell Lung Cancer
2.6 Prognosis
2.6.1 Breast Cancer
2.6.2 Leukemia
2.6.3 Lymphoma
2.6.4 Melanoma
2.6.5 Non-Small Cell Lung Cancer
2.7 Treatment

3 Key Marketed Products
3.1 Overview
3.2 Revlimid (lenalidomide) - Celgene
3.3 Opdivo (nivolumab) - Ono Pharma/Bristol-Myers Squibb
3.4 Keytruda (pembrolizumab) - Merck & Co.
3.5 Tecentriq (atezolizumab) - Roche
3.6 Darzalex (daratumumab) - Johnson & Johnson
3.7 Imfinzi (durvalumab) - AstraZeneca/Celgene
3.8 Gardasil/Gardasil 9 (human papillomavirus vaccine) - Merck & Co.
3.9 Pomalyst/Imnovid (pomalidomide) - Celgene
3.10 Yescarta (axicabtagene ciloleucel) - Gilead Sciences
3.11 Gazyva (obinutuzumab) - Roche
3.12 Yervoy (ipilimumab) - Bristol-Myers Squibb
3.13 Rituxan (rituximab) - Roche/Biogen
3.14 Kymriah (tisagenlecleucel) - Novartis

4 Pipeline Landscape Assessment
4.1 Overview
4.2 Pipeline Development Landscape
4.3 Molecular Targets in the Pipeline
4.4 Clinical Trials Landscape
4.4.1 Clinical Trial Failure Rates
4.4.2 Clinical Trial Duration
4.4.3 Clinical Trial Size
4.4.4 Cumulative Clinical Trial Size
4.5 Late-Stage Drugs of the Developmental Pipeline
4.5.1 Lisocabtagene maraleucel - Juno Therapeutics/Celgene
4.5.2 Durvalumab plus Tremelimumab - AstraZeneca
4.5.3 Tremelimumab - AstraZeneca
4.5.4 Cemiplimab - Regeneron/Sanofi
4.5.5 Epacadostat - Incyte Corp
4.5.6 Axalimogene filolisbac - Advaxis

5 Multi-scenario Market Forecast to 2024
5.1 Overall Market Size
5.2 Generic Penetration
5.3 Revenue Forecast by Molecular Target
5.3.1 Immune Checkpoint Proteins
5.3.2 Tumor Associated Antigens
5.3.3 Cytokine Signaling
5.3.4 HPV

6 Company Analysis and Positioning
6.1 Revenue and Market Share Analysis by Company
6.1.1 Celgene - Revlimid to Maintain Celgene’s Position as Market Leader
6.1.2 Merck & Co. - Keytruda Key to Cancer Immunotherapy Market Growth
6.1.3 Bristol-Myers Squibb - Opdivo to Drive Revenue from Cancer Immunotherapies
6.1.4 Roche - Strong Revenue from Tecentriq and Gazyva Set to Offset Loss from Rituxan
6.1.5 AstraZeneca - Revenue from Imfinzi set to Drive Growth amid Growing Immunotherapy Presence
6.1.6 Johnson & Johnson - Darzalex Key to Strong Growth
6.1.7 Novartis - Diverse Cancer Immunotherapies Portfolio Contributes Small Portion to Overall Revenue
6.1.8 AbbVie - Recent New Approvals to Result in AbbVie Becoming a Leading Player in 2024
6.1.9 Gilead Sciences - Growth Driven by CAR-T Therapy Yescarta
6.1.10 Amgen - Rituximab Biosimilar to Drive Growth for Amgen in a Portfolio with No Novel Blockbusters
6.2 Market and Pipeline Company Landscape

7 Strategic Consolidations
7.1 Licensing Deals
7.1.1 Deals by Region, Deal Value and Year
7.1.2 Deals by Indication and Deal Value
7.1.3 Deals by Stage of Development and Deal Value
7.1.4 Deals by Molecule Type, Molecular Target and Deal Value
7.1.5 Table for Licensing Deals with Disclosed Deal Value
7.2 Co-development Deals
7.2.1 Deals by Region, Deal Value and Year
7.2.2 Deals by Indication and Deal Value
7.2.3 Deals by Stage of Development and Deal Value
7.2.4 Deals by Molecule Type, Molecular Target and Deal Value
7.2.5 Table for Co-development Deals with Disclosed Deal Value

8 Appendix
8.1 References
8.2 Figures of All Clinical Stage Pipeline Products
8.3 Abbreviations
8.4 Disease List
8.5 Methodology
8.5.1 Coverage
8.5.2 Secondary Research
8.5.3 Market Size and Revenue Forecasts
8.5.4 Pipeline Analysis
8.5.5 Competitive Landscape
8.6 Contact Us
8.7 Disclaimer

1.1 List of Tables
Table 1: Cancer Immunotherapies Drugs Market, Global, Breast Cancer Histopathological and Molecular Classification, 2018
Table 2: Cancer Immunotherapies Drugs Market, 7MM, Epidemiology of Key Indications, 2016
Table 3: Cancer Immunotherapies Drugs Market, US, Breast Cancer Stage at Diagnosis and Five-Year Relative Survival Rate (%), 2016
Table 4: Cancer Immunotherapies Drugs Market, US, Leukemia Subtype and Five-Year Survival Rates (%), 2016
Table 5: Cancer Immunotherapies Drugs Market, US, Lymphoma Subtype and Survival Rates (%), 2016
Table 6: Cancer Immunotherapies Drugs Market, US, Cutaneous Melanoma Stage and Survival Rates (%), 2016
Table 7: Cancer Immunotherapies Drugs Market, US, NSCLC Stage at Diagnosis and Five-Year Relative Survival (%), 2017
Table 8: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Revlimid, 2018
Table 9: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Opdivo, 2018
Table 10: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Keytruda, 2018
Table 11: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Tecentriq, 2018
Table 12: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Darzalex, 2018
Table 13: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications Imfinzi, 2018
Table 14: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Gardasil, 2018
Table 15: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Pomalyst, 2018
Table 16: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Yescarta, 2018
Table 17: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Gazyva, 2018
Table 18: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Yervoy, 2018
Table 19: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Rituxan, 2018
Table 20: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Kymriah, 2018
Table 21: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Key Products ($bn), 2017-2024
Table 22: Cancer Immunotherapies Drugs Market, Global, Forecast Revenue by Company, 2017-2024
Table 23: Cancer Immunotherapies Drugs Market, Global, Licensing Deals, 2006-2018
Table 24: Cancer Immunotherapies Drugs Market, Global, Co-development Deals, 2006-2018

1.2 List of Figures
Figure 1: Cancer Immunotherapies Drugs Market, Global, Frequency of Molecular Aberrations in Non-Small Cell Lung Cancer (%), 2018
Figure 2: Cancer Immunotherapies Drugs Market, 7MM, Epidemiology Patterns for Breast Cancer, 2016-2023
Figure 3: Cancer Immunotherapies Drugs Market, 7MM, Epidemiology Patterns for Leukemia, 2016-2023
Figure 4: Cancer Immunotherapies Drugs Market, 7MM, Epidemiology Patterns for Lymphoma, 2016-2023
Figure 5: Cancer Immunotherapies Drugs Market, 7MM, Epidemiology Patterns for Cutaneous Melanoma, 2016-2023
Figure 6: Cancer Immunotherapies Drugs Market, 7MM, Epidemiology Patterns for NSCLC, 2016-2023
Figure 7: Cancer Immunotherapies Drugs Market, Global, Key Marketed Products and Approved Indications, 2018
Figure 8: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Revlimid ($bn), 2006-2024
Figure 9: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Opdivo ($bn), 2014-2024
Figure 10: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Keytruda ($bn), 2014-2024
Figure 11: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Tecentriq ($bn), 2016-2024
Figure 12: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Darzalex ($bn), 2015-2024
Figure 13: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Imfinzi ($bn), 2017-2024
Figure 14: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Gardasil ($bn), 2006-2024
Figure 15: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Pomalyst ($bn), 2013-2024
Figure 16: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Yescarta ($bn), 2018-2024
Figure 17: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Gazyva ($bn), 2013-2024
Figure 18: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Yervoy ($bn), 2011-2024
Figure 19: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Rituxan ($bn), 2006-2024
Figure 20: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Kymriah ($bn), 2017-2024
Figure 21: Cancer Immunotherapies Drugs Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2018
Figure 22: Cancer Immunotherapies Drugs Market, Global, Cancer Immunotherapies Pipeline by Stage of Development, Molecule Type and Program Type, 2018
Figure 23: Cancer Immunotherapies Drugs Market, Global, Pipeline for Key Indications by Stage of Development, 2018
Figure 24: Cancer Immunotherapies Drugs Market, Global, Pipeline for Key Indications by Molecule Type, 2018
Figure 25: Cancer Immunotherapies Drugs Market, Global, Cancer Immunotherapies Pipeline by Molecular Target, 2018
Figure 26: Cancer Immunotherapies Drugs Market, Global, Pipeline for Key Indications by Molecular Target, 2018
Figure 27: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rate by Stage of Development (%), 2006-2018
Figure 28: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006-2018
Figure 29: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2018
Figure 30: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2018
Figure 31: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2018
Figure 32: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2018
Figure 33: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2018
Figure 34: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2018
Figure 35: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Size by Stage of Development (participants), 2006-2018
Figure 36: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006-2018
Figure 37: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2018
Figure 38: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006-2018
Figure 39: Cancer Immunotherapies Drugs Market, Global, Clinical Program Size by Stage of Development (participants), 2006-2018
Figure 40: Cancer Immunotherapies Drugs Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006-2018
Figure 41: Cancer Immunotherapies Drugs Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006-2018
Figure 42: Cancer Immunotherapies Drugs Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006-2018
Figure 43: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Lisocabtagene maraleucel ($m), 2018-2024
Figure 44: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Durvalumab plus Tremelimumab ($m), 2018-2024
Figure 45: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Tremelimumab ($m), 2018-2024
Figure 46: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Cemiplimab ($m), 2019-2024
Figure 47: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Epacadostat ($bn), 2020-2024
Figure 48: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Axalimogene filolisbac ($m), 2020-2024
Figure 49: Cancer Immunotherapies Drugs Market, Global, Market Size ($bn), 2017-2024
Figure 50: Cancer Immunotherapies Drugs Market, Global, Key Products Market Share, 2017-2024
Figure 51: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Premium and Generic Products ($bn), 2017-2024
Figure 52: Cancer Immunotherapies Market, Global, Annual Revenue Forecast for Immune Checkpoint Proteins ($bn), 2017-2024
Figure 53: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Tumor Associated Antigens ($bn), 2017-2024
Figure 54: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Cytokine Signaling ($bn), 2017-2024
Figure 55: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for HPV Vaccines ($bn), 2017-2024

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Celgene
  • Merck & Co.
  • Bristol-Myers Squibb
  • Roche
  • AstraZeneca
  • Johnson & Johnson
  • Novartis
  • AbbVie
  • Gilead Sciences
  • Amgen
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll